This is further supported by previous research showing that melanoma patients with high counts of peripheral blood CD8+ T cells or high expression of the T cell activation marker HLA-DR prior to M-ILP were more likely to achieve CR (7, 8). This evidence concerns the gene CD8A and melanoma.